Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume

Real-time OTC Markets

More quotes

Market Closed - OTC Markets 02:14:20 23/01/2026 am IST			5-day change	1st Jan Change
0.007000 ^USD	+366.67%		+1,650.00%	+366.67%

15/23/15	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/23/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Market Cap	85.73T 77.53T 71.56T 64.77T 1L 80.6L 1L 9L 3L 43.09L 3L 3L 1.37Cr	P/E 2021	-16.6x	P/E 2022	-3.24x
Enterprise Value	39.16L 35.42L 32.69L 29.59L 55.84L 37Cr 57.51L 3.92Cr 1.56Cr 20Cr 1.47Cr 1.44Cr 63Cr	EV / Sales 2021	93,97,88,53,933x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

15/23/15	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/23/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
31/23/31	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/23/30	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/22/11	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
13/22/13	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
31/22/31	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	CI
12/22/12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
17/22/17	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/22/16	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/22/28	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	CI
18/22/18	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	CI
11/21/11	Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	CI

07/23/07	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	PU
31/23/31	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
21/23/21	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	AQ
13/22/13	Rapid Therapeutic Science Laboratories Updates Patents	AQ
11/22/11	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Rapid Therapeutic Science Laboratories, Inc. Share Price

Stocks

RTSL

US7534312043

Pharmaceuticals

Valuation: Rapid Therapeutic Science Laboratories, Inc.

Chart: Rapid Therapeutic Science Laboratories, Inc.

Latest news: Rapid Therapeutic Science Laboratories, Inc.

Press Releases: Rapid Therapeutic Science Laboratories, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Rapid Therapeutic Science Laboratories, Inc.

Latest insider transactions

Alternative Medicine

Financials

Company Profile

Quotes

1 day	+366.67%
1 week	+1,650.00%
Current month	+1,650.00%
1 month	+1,650.00%
3 months	+6,900.00%
6 months	+16.67%
Current year	+366.67%

1 week	0		0.01
1 month	0		0.01
Current year	0		0.01
1 year	0		0.01
3 years	0		0.01
5 years	0		9.98
10 years	0		125

Manager	Title	Age	Since
Donal Schmidt CEO	Chief Executive Officer	65	15/11/2019
D. Watler DFI	Director of Finance/CFO	77	15/11/2019

Director	Title	Age	Since
D. Watler BRD	Director/Board Member	77	15/11/2019
Donal Schmidt BRD	Director/Board Member	65	15/11/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/12/21	Sean Berrier	Don	Executive/Senior Manager	20,00,000	1.0332%
27/12/21	Texas Mdi, Inc.	Don	Company	20,00,000	1.0332%
27/08/21	Henry Punzi	Other	Director	1,25,000	0.0646%

	2021	2022
Net sales	0 0 0 0 0 0.05 0 0.01 0 0.03 0 0 0.09	-
Net income	-28.68L -25.93L -23.94L -21.67L -40.89L -27Cr -42.11L -2.87Cr -1.14Cr -14Cr -1.08Cr -1.05Cr -46Cr	-17.95L -16.23L -14.98L -13.56L -25.59L -17Cr -26.36L -1.8Cr -71.46L -9.02Cr -67.36L -65.92L -29Cr
Net Debt	17.93L 16.21L 14.97L 13.55L 25.56L 17Cr 26.33L 1.8Cr 71.39L 9.01Cr 67.29L 65.86L 29Cr	38.31L 34.64L 31.98L 28.94L 54.62L 36Cr 56.25L 3.84Cr 1.53Cr 19Cr 1.44Cr 1.41Cr 61Cr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	+366.67%	+1,650.00%	+366.67%	+75.00%	5.7T
ELI LILLY AND COMPANY	-0.70%	+4.58%	+40.23%	+138.79%	1,27100Cr
JOHNSON & JOHNSON	+1.11%	+4.11%	+45.85%	+92.54%	68TCr
ABBVIE INC.	-0.18%	+2.15%	+26.25%	+112.46%	52TCr
ROCHE HOLDING AG	-0.53%	+3.87%	+39.84%	+69.80%	39TCr
MERCK & CO., INC.	-0.16%	+0.01%	+60.69%	+44.94%	36TCr
NOVARTIS AG	+0.16%	+1.20%	+27.37%	+59.16%	30TCr
ASTRAZENECA PLC	+0.39%	+0.42%	+3.66%	+36.49%	29TCr
AMGEN INC.	-0.22%	+1.47%	+38.89%	+74.73%	25TCr
GILEAD SCIENCES, INC.	-1.05%	+0.23%	+36.10%	+121.22%	21TCr
Average	+36.55%	+1.56%	+68.56%	+82.51%	43TCr
Weighted average by Cap.	-0.14%	+2.67%	+37.49%	+96.84%